Key Highlights

• EchoIQ enters a research collaboration with Mayo Clinic Arizona to evaluate its proprietary AI platform for cardiac risk stratification in oncology patients, targeting the cardio-oncology sector driven by rising cancer survival rates and treatment-related cardiovascular complications.
• The study will assess whether EchoIQ’s AI model can generate predictive heart failure risk scores from standard echocardiographic data in patients undergoing cancer therapy, with completion and co-authored publication expected in the first half of CY2027.
• EIQ shares gained 0.42% to A$1.19 on 12 June 2026, a measured response that may reflect investors awaiting study outcomes rather than…